Division of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Biotechnology Division, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Front Immunol. 2021 Feb 19;12:611761. doi: 10.3389/fimmu.2021.611761. eCollection 2021.
Misfolded proteins, inflammation, and vascular alterations are common pathological hallmarks of neurodegenerative diseases. Alpha-synuclein is a small synaptic protein that was identified as a major component of Lewy bodies and Lewy neurites in the brain of patients affected by Parkinson's disease (PD), Lewy body dementia (LBD), and other synucleinopathies. It is mainly involved in the regulation of synaptic vesicle trafficking but can also control mitochondrial/endoplasmic reticulum (ER) homeostasis, lysosome/phagosome function, and cytoskeleton organization. Recent evidence supports that the pathological forms of α-synuclein can also reduce the release of vasoactive and inflammatory mediators from endothelial cells (ECs) and modulates the expression of tight junction (TJ) proteins important for maintaining the blood-brain barrier (BBB). This hints that α-synuclein deposition can affect BBB integrity. Border associated macrophages (BAMs) are brain resident macrophages found in association with the vasculature (PVMs), meninges (MAMs), and choroid plexus (CPMs). Recent findings indicate that these cells play distinct roles in stroke and neurodegenerative disorders. Although many studies have addressed how α-synuclein may modulate microglia, its effect on BAMs has been scarcely investigated. This review aims at summarizing the main findings supporting how α-synuclein can affect ECs and/or BAMs function as well as their interplay and effect on other cells in the brain perivascular environment in physiological and pathological conditions. Gaps of knowledge and new perspectives on how this protein can contribute to neurodegeneration by inducing BBB homeostatic changes in different neurological conditions are highlighted.
错误折叠的蛋白质、炎症和血管改变是神经退行性疾病的常见病理特征。α-突触核蛋白是一种小的突触蛋白,它被鉴定为帕金森病(PD)、路易体痴呆(LBD)和其他突触核蛋白病患者大脑中路易体和路易神经纤维的主要成分。它主要参与调节突触囊泡运输,但也可以控制线粒体/内质网(ER)稳态、溶酶体/吞噬体功能和细胞骨架组织。最近的证据支持病理性α-突触核蛋白形式也可以减少血管活性和炎症介质从内皮细胞(ECs)的释放,并调节维持血脑屏障(BBB)的紧密连接(TJ)蛋白的表达。这表明α-突触核蛋白沉积会影响 BBB 的完整性。边界相关巨噬细胞(BAMs)是与血管(PVMs)、脑膜(MAMs)和脉络丛(CPMs)相关的脑驻留巨噬细胞。最近的发现表明,这些细胞在中风和神经退行性疾病中发挥着不同的作用。尽管许多研究都探讨了α-突触核蛋白如何调节小胶质细胞,但它对 BAMs 的影响却很少被研究。这篇综述旨在总结主要的发现,这些发现支持α-突触核蛋白如何影响 ECs 和/或 BAMs 的功能,以及它们在生理和病理条件下在脑血管周围环境中与其他细胞的相互作用及其对其他细胞的影响。强调了在不同神经退行性疾病中,通过诱导 BBB 稳态变化,这种蛋白质如何导致神经退行性变的知识空白和新视角。